Paying user area
Try for free
Allergan PLC pages available for free this week:
- Income Statement
- Balance Sheet: Assets
- Common-Size Balance Sheet: Assets
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Common Stock Valuation Ratios
- Present Value of Free Cash Flow to Equity (FCFE)
- Selected Financial Data since 2005
- Operating Profit Margin since 2005
- Price to Book Value (P/BV) since 2005
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Allergan PLC for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Current Enterprise Value (EV)
Current share price (P) | |
No. shares of common stock outstanding | |
US$ in thousands | |
Common equity (market value)1 | |
Add: Preferred shares, $0.0001 par value per share (per books) | |
Add: Noncontrolling interest (per books) | |
Total equity | |
Add: Current portion of long-term debt and capital leases (per books) | |
Add: Long-term debt and capital leases, excluding current portion (per books) | |
Total equity and debt | |
Less: Cash and cash equivalents | |
Less: Marketable securities | |
Enterprise value (EV) |
Based on: 10-K (reporting date: 2019-12-31).
1 Common equity (market value) = Share price × No. shares of common stock outstanding
= ×
Historical Enterprise Value (EV)
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
1 Data adjusted for splits and stock dividends.
2 Closing price as at the filing date of Allergan PLC Annual Report.
3 2019 Calculation
Common equity (market value) = Share price × No. shares of common stock outstanding
= ×
The financial data reveals a clear downward trend in both common equity (market value) and total equity from 2015 through 2018, followed by a recovery in 2019. Specifically, common equity decreased substantially from 117,644,469 thousand US dollars at the end of 2015 to 46,256,695 thousand US dollars by the end of 2018, before rebounding to 65,142,399 thousand US dollars in 2019. Total equity showed a similar pattern, declining from 122,572,069 thousand US dollars in 2015 to 46,273,595 thousand US dollars in 2018, then rising to 65,165,199 thousand US dollars in 2019.
Total equity and debt consistently declined between 2015 and 2018, dropping from 165,298,269 thousand US dollars to 70,071,295 thousand US dollars, indicating a reduction in the company’s combined financing from equity and liabilities. However, this measure increased in 2019 to 87,814,199 thousand US dollars, suggesting a partial recovery or renewed financing activity.
Enterprise value exhibited a downward trajectory from the end of 2015 through 2018, decreasing from 164,192,969 thousand US dollars to 68,163,995 thousand US dollars. In 2019, enterprise value increased to 81,899,299 thousand US dollars, reflecting a similar recovery pattern as equity and total capital employed.
- Equity Trends
- Both common equity and total equity substantially declined during the four-year span from 2015 to 2018, indicating reduced shareholder value and possibly net losses or distributions exceeding earnings. The recovery in 2019 suggests an improvement in financial position or market perception.
- Total Equity and Debt
- The consistent decrease through 2018 shows a contraction in the company's total capitalization, while the rise in 2019 reflects a rebound in capital structure, possibly through new debt issuance or equity financing.
- Enterprise Value
- The initial decline implies a diminishing overall valuation from the market and debt holders' perspectives, aligned with falling equity and financial scale. The uptick in 2019 indicates improved market conditions or operational performance affecting valuation positively.